Surgical resection of advanced gastric cancer following trastuzumab/oxaliplatin/capecitabine combination therapy

Figure 1 Fluorescence in situ hybridization analysis showing positive human epidermal growth factor receptor 2 expression with cluster amplification (ratio > 2. 2).

Figure 2 Radiological evaluation by computed tomography scan before (A) and after three cycles (B) of neoadjuvant therapy of trastuzumab combined with oxaliplatin and capecitabine. The thickness of the stomach wall and the size of the lymph nodes had decreased dramatically.